Insights into Fibrolamellar Carcinoma Lead to New Clinical Trial
• Researchers have identified a unique transcriptomic signature for fibrolamellar hepatocellular carcinoma (FLC), distinguishing it from other liver cancers. • A clinical trial has been initiated, combining DT2216 and irinotecan, showing promise in preliminary results against FLC. • The study highlights the importance of examining tumor margins for hidden FLC cells to prevent potential recurrence. • The research suggests defining cancer by its impact on protein activity balance rather than solely by DNA changes.
Novel Enzyme Shows Promise in Treating IgG-Mediated Autoimmune Diseases
Researchers at Emory University have identified a novel enzyme, CU43, that effectively reduces IgG-mediated pathologies in mouse models of autoimmune diseases.